The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
Abstract
BACKGROUND: Implementation of appropriate oral anticoagulant treatment for the prevention of stroke in very elderly patients with atrial fibrillation is challenging because of concerns regarding bleeding. METHODS: We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled, event-driven trial to compare a once-daily 15-mg dose of edoxaban with placebo in elderly Japanese patients (≥80 years of age) with nonvalvular atrial fibrillation who were not considered to be appropriate candidates for oral anticoagulant therapy at doses approved for stroke prevention. The primary efficacy end point was the composite of stroke or systemic embolism, and the primary safety end point was major bleeding according to the definition of the International Society on Thrombosis and Haemostasis. RESULTS: A total of 984 patients were randomly assigned in a 1:1 ratio to receive a daily dose of 15 mg of edoxaban (492 patients) or placebo (492 patients). A total of 681 patients completed the trial, and 303 discontinued (158 withdrew, 135 died, and 10 had other reasons); the numbers of patients who discontinued the trial were similar in the two groups. The annualized rate of stroke or systemic embolism was 2.3% in the edoxaban group and 6.7% in the placebo group (hazard ratio, 0.34; 95% confidence interval [CI], 0.19 to 0.61; P<0.001), and the annualized rate of major bleeding was 3.3% in the edoxaban group and 1.8% in the placebo group (hazard ratio, 1.87; 95% CI, 0.90 to 3.89; P = 0.09). There were substantially more events of gastrointestinal bleeding in the edoxaban group than in the placebo group. There was no substantial between-group difference in death from any cause (9.9% in the edoxaban group and 10.2% in the placebo group; hazard ratio, 0.97; 95% CI, 0.69 to 1.36). CONCLUSIONS: In very elderly Japanese patients with nonvalvular atrial fibrillation who were not appropriate candidates for standard doses of oral anticoagulants, a once-daily 15-mg dose of edoxaban was superior to placebo in preventing stroke or systemic embolism and did not result in a significantly higher incidence of major bleeding than placebo. (Funded by Daiichi Sankyo; ELDERCARE-AF ClinicalTrials.gov number, NCT02801669.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citationGo, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,205
2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellá, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.11.033 · Cited by 1,801
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
A New Risk Scheme to Predict Warfarin-Associated Hemorrhage
Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., & Singer, D. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.031 · Cited by 852
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Yasuda, S., Kaikita, K., Akao, M., Ako, J., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904143 · Cited by 565
Self-citationRuff, C. T., Giugliano, R. P., Braunwald, E., Morrow, D. A., Murphy, S. A., Kuder, J. F., Deenadayalu, N., Jarolim, P., Betcher, J., Shi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61943-7 · Cited by 405
Makizako, H., Shimada, H., Doi, T., Tsutsumimoto, K., & Suzuki, T. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008462 · Cited by 304
Kato, E. T., Giugliano, R. P., Ruff, C. T., Koretsune, Y., Yamashita, T., Kiss, R. G., Nordio, F., Murphy, S. A., Kimura, T., Jin, J., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003432 · Cited by 288
Self-citationSato, H., Ishikawa, K., Kitabatake, A., Ogawa, S., Maruyama, Y., Yokota, Y., Fukuyama, T., Doi, Y., Mochizuki, S., Izumi, T., et al. (2006) · Stroke · doi:10.1161/01.str.0000198839.61112.ee · Cited by 282
Rich, M. W., Chyun, D. A., Skolnick, A. H., Alexander, K. P., Forman, D. E., Kitzman, D. W., Maurer, M. S., McClurken, J. B., Resnick, B. M., Shen, W. K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000380 · Cited by 219
Akao, M., Chun, Y., Esato, M., Abe, M., Tsuji, H., Wada, H., Hasegawa, K., & on behalf of the Fushimi AF Registry Investigators (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0344 · Cited by 135
Self-citationYamashita, T., Koretsune, Y., Yang, Y., Chen, S., Chung, N., Shimada, Y. J., Kimura, T., Miyazaki, K., Abe, K., Mercuri, M. F., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-1082 · Cited by 113
Self-citationYamashita, Y., Hamatani, Y., Esato, M., Chun, Y., Tsuji, H., Wada, H., Hasegawa, K., Abe, M., Lip, G. Y. H., & Akao, M. (2015) · CHEST Journal · doi:10.1378/chest.15-1095 · Cited by 85
Self-citationKoretsune, Y., Yamashita, T., Kimura, T., Fukuzawa, M., Abe, K., & Yasaka, M. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-0942 · Cited by 75
Self-citationBonde, A. N., Lip, G. Y. H., Kamper, A., Fosbøl, E. L., Stærk, L., Carlson, N., Torp-Pedersen, C. T., Gislason, G., & Olesen, J. B. (2016) · Stroke · doi:10.1161/strokeaha.116.014422 · Cited by 67
Self-citationOverview of oral antithrombotic treatment in elderly patients with atrial fibrillation
Kato, E. T., Goto, S., & Giugliano, R. P. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.006 · Cited by 52
G, S. K. C., Danik, S. B., Altman, R., Barrett, C. D., Lip, G. Y. H., Chatterjee, S., Roubin, G. S., Natale, A., & Danik, J. S. (2015) · Cardiology in Review · doi:10.1097/crd.0000000000000088 · Cited by 50
Self-citationOkumura, K., Lip, G. Y. H., Akao, M., Tanizawa, K., Fukuzawa, M., Abe, K., Akishita, M., & Yamashita, T. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.08.017 · Cited by 38
Self-citation
Cited by
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Self-citationAndrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes
Kirchhof, P., Toennis, T., Goette, A., Camm, A. J., Diener, H. C., Becher, N., Bertaglia, E., Blomstrom Lundqvist, C., Borlich, M., Brandes, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303062 · Cited by 418
Self-citationCai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Kumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC · doi:10.1016/j.jacc.2026.05.033 · Cited by 2
Metadata
- Authors
- Okumura, K., Akao, M., Yoshida, T., Kawata, M., Okazaki, O., Akashi, S., Eshima, K., Tanizawa, K., Fukuzawa, M., Hayashi, T., Akishita, M., Lip, G. Y. H., & Yamashita, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-29
- Volume
- 383
- Issue
- 18
- Pages
- 1735-1745
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3082179368
- Cited by
- 344
- References
- 28
- FWCI
- 25.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.